Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

Jean B. Nachega,1,2,3,4,5 Jean-Jacques Parienti,5,6,5a Olalekan A. Uthman,7,8,9 Robert Gross,10 David W. Dowdy,7 Paul E. Sax,11 Joel E. Gallant,12 Michael J. Mugaero,13 Edward J. Mills,14 and Thomas P. Giordano15

1Department of Epidemiology, Pittsburgh University Graduate School of Public Health, Pennsylvania; 2Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 3Department of Medicine, and 4Centre for Infectious Diseases, Faculty of Medicine & Health Sciences, Stellenbosch University, Cape Town, South Africa; 5Department of Biostatistics and Clinical Research, Côte de Nacre University, Côte de Nacre Teaching Hospital; 6Faculté de Médecine, Université de Caen Basse-Normandie, EA 4655 Risque Microbien, Caen, France; 7Division of Health Sciences, Warwick Centre for Applied Health Research and Delivery (WCARHID), Warwick Medical School, The University of Warwick, Coventry, and 8Liverpool School of Tropical Medicine, International Health Group, United Kingdom; 9Centre for Evidence-based Health Care, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa; 10Perelman School of Medicine, and Philadelphia Veterans Affairs Medical Center, University of Pennsylvania; 11Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts; 12Southwest CARE Center, Santa Fe, New Mexico; 13University of Alabama at Birmingham; 14Faculty of Health Sciences, University of Ottawa, Ontario, Canada; and 15Department of Medicine, Baylor College of Medicine, and The Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas

Background. Contemporary antiretroviral treatment regimens are simpler than in the past, with lower pill burden and once-daily dosing frequency common. We performed a meta-analysis of randomized controlled trials (RCTs) to investigate the impact of pill burden and once-daily vs twice-daily dosing on ART adherence and virological outcomes.

Methods. A literature search of 4 electronic databases through 31 March 2013 was used. RCTs comparing once-daily vs twice-daily ART regimens that also reported on adherence and virological suppression were included. Study design, study population characteristics, intervention, outcome measures, and study quality were extracted. Study quality was rated using the Cochrane risk-of-bias tool.

Results. Nineteen studies met our inclusion criteria (N = 6312 adult patients). Higher pill burden was associated with both lower adherence rates (P = .004) and worse virological suppression (P < .0001) in both once-daily and twice-daily subgroups, although the association with adherence in the once-daily subgroup was not statistically significant. The average adherence was modestly higher in once-daily regimens than twice-daily regimens (weighted mean difference = 2.55%; 95% confidence interval [CI], 1.23 to 3.87; P = .0002). Patients on once-daily regimens did not achieve virological suppression more frequently than patients on twice-daily regimens (relative risk [RR] = 1.01; 95% CI, 0.99 to 1.03; P = .50). Both adherence and viral load suppression decreased over time, but adherence decreased less with once-daily dosing than with twice-daily dosing.

Conclusions. Lower pill burden was associated with both better adherence and virological suppression. Adherence, but not virological suppression, was slightly better with once- vs twice-daily regimens.

Keywords. randomized controlled trials; ART; fixed-dose combination; once-daily; twice-daily.
METHODS

Protocol and Registration
The study background, rationale, and methods were specified in advance and documented in a protocol that was published in the PROSPERO register (CRD42012002515).

Inclusion Criteria
We included only randomized controlled trials (RCTs) that compared once-daily vs twice-daily regimens in either ART-naive or -experienced patients with objective measures of adherence and measures of virological outcomes.

Search Strategy
We systematically searched the following databases from their inception until 31 March 2013 (including those years searched by the Parienti meta-analysis): Cochrane CENTRAL, PubMed, Google scholar, and Web of Science. Our search terms included the following: "HIV," "treatment simplification," "coformulation," "fixed-dose combination," "QD," "twice-daily," "once-daily," "adherence," "HAART," "ART," "cART," and "patient preference." We also searched abstracts from major HIV/AIDS and infectious diseases conferences (from 2008 onward) including Conference on Retrovirus and Opportunistic Infections, International AIDS Conference, International AIDS Society Conference on HIV Treatment, Pathogenesis and Prevention, International Conference on Antimicrobial Agents and Chemotherapy, and Infectious Diseases Society of America Conference. In addition, the bibliographies of relevant review articles, metaanalyses, and selected articles were examined for pertinent studies.

Study Selection
We evaluated each identified study using the following predetermined selection criteria: open-label RCTs of HIV-infected subjects either ART naive or ART experienced that compared once-daily ART regimens with any twice-daily antiretroviral regimens and assessed both adherence (using objective measures, such as pill count or medication event monitoring system [MEMS]) and viral suppression (percentage of subjects with HIV-1 RNA levels < 50 copies/mL or < 200 copies/mL in the intent-to-treat, missing-equals-failure analysis). Placebo-controlled, blinded trials were excluded because the regimen frequency was identical for the comparator arms (to maintain blinding) and, therefore, the impact of the placebo on adherence could not be measured. We chose to exclude trials that used self-reported adherence as the patients are more likely to overestimate adherence due to social desirability and typically these trials do not reflect true variability in adherence due to a ceiling effect [27–30].

Validity Assessment
We used the Cochrane Collaboration’s tool for assessing the risk of bias for quality assessment of the included studies [31]. The studies were graded based on the following: sequence generation, blinding of outcome assessor, incomplete outcome data, selective outcome reporting, and other sources of bias. The other sources of bias considered whether the analysis was intention-to-treat. We summarized the global assessment for each trial as low risk, unclear, or high risk of bias.

Data Extraction
Three reviewers (O. A. U., J. J. P., and J. B. N.) independently evaluated the eligibility and methodological quality of studies.
obtained from the literature search. These same reviewers also independently extracted and compared the data. For each identified study that met the selection criteria, details on study design, study population characteristics, intervention, outcome measures, and study quality were extracted. Discrepancies were resolved by consensus through discussion.

Summary Measures
The primary measures of treatment effects were weighted mean difference (WMD) with 95% confidence interval (CI) for adherence to treatment and relative risk (RR) with 95% CI for virological suppression. We used the following methods to compute effect sizes, when incompletely reported: contact with the corresponding author; estimation of the standard deviation (SD) on the basis of the sample size, median, and range as suggested by Hozo and colleagues [32] or on the basis of the sample size and P value; and imputation of the SD reported in similar studies.

Statistical Analysis
The Spearman rank correlation coefficient (rho) was used to examine the associations between regimen pill burden (daily number of tablets), length of follow-up period, adherence rates, and virological response. We used DerSimonian and Laird [33] random effect models to synthesize results across studies due to anticipated heterogeneity resulting from the differences in methodology, population, and ART regimen. Between-study heterogeneity was assessed using the $I^2$ statistic, which reports the percentage of total variation across studies due to heterogeneity rather than chance [34, 35]. Based on a significant interaction previously found in the meta-analysis by Parienti et al [12], subgroup analyses were prespecified to explore the reasons for heterogeneity. These were based on patient characteristics at baseline, including the following: treatment-naive individuals initiating their first regimens of ART, treatment-experienced individuals with virological suppression, and treatment-experienced individuals with treatment failure (ie, lack of virological suppression).

We examined the reliability and conclusiveness of the available evidence using a trial sequential analysis (TSA) [36–39] and the sample size required for a reliable and conclusive meta-analysis. Therefore, we calculated the sample size (ie, the heterogeneity-corrected optimal information size [HOIS]) required to detect or reject a once-daily regimen intervention effect of minimal relevant difference of 2 percentage points in mean adherence and a 10% RR difference in viral suppression. We then used the HOIS to construct Lan-DeMets sequential monitoring boundaries for our cumulative metaanalyses analogous to interim monitoring in an RCT [36–39]. We conducted the TSA with the intention of maintaining an overall 5% risk of a type I error and 20% risk of a type II error.

RESULTS
Study Selection and Characteristics
The literature search yielded 428 articles (Figure 1). After review, 46 articles were selected for critical reading. Of the 46 articles, 27 did not meet the inclusion criteria and were excluded. Nineteen studies [5, 17–19, 21, 22, 24, 41–49, 51–53] with usable outcome data involving 6312 individuals met the inclusion criteria and were included. Table 1 shows the characteristics of the included studies. The studies were published between 2004 and 2011; 11 studies with 3029 patients were included in the earlier meta-analysis [12] and 8 additional studies with 3283 patients.
were identified. Most studies (18/19; 95%) were published in peer-reviewed journals. Seven studies (37%) included treatment-naïve patients, 9 (47%) evaluated treatment-experienced patients with suppressed viral loads, and 3 (16%) evaluated treatment-experienced patients with unsuppressed viral loads. The median duration of follow-up was 48 weeks (range, 4–96 weeks). Most studies (N = 17; 89%) reported both adherence and virological suppression. Eleven studies (58%) used MEMS to measure adherence, and 8 studies used pill count ratio. Supplementary Table 1 shows the characteristics of studies that were excluded from the meta-analysis, and Supplementary Table 2 shows the assessment of bias risk among the included studies.

Pill Burden
There was a negative and statistically significant association (Figure 2A) between adherence and pill burden (Spearman

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Once-Daily Regimen</th>
<th>Twice-Daily Regimen</th>
<th>Population</th>
<th>Follow-up, weeks</th>
<th>Means of Assessing Adherence</th>
<th>Outcomes Reported</th>
<th>Risk of Bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benson [41]</td>
<td>2004</td>
<td>FTC, D4T or AZT,</td>
<td>3TC, D4T or AZT,</td>
<td>Experienced-controlled</td>
<td>48</td>
<td>Pill count</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and an NNRTI or a PI</td>
<td>and an NNRTI or a PI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eron [43]</td>
<td>2004</td>
<td>LPV/r and NRTIs</td>
<td>LPV/r and NRTIs</td>
<td>Treatment-naïve</td>
<td>48</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Sosa [53]</td>
<td>2005</td>
<td>ABC, 3TC, and a PI</td>
<td>ABC, 3TC, and a PI</td>
<td>Experienced-controlled</td>
<td>48</td>
<td>Pill count</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Gallant [5]</td>
<td>2006</td>
<td>TDF, FTC, and EFV</td>
<td>AZT, 3TC, and EFV</td>
<td>Treatment-naïve</td>
<td>48</td>
<td>Pill count</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Kubota [44]</td>
<td>2006</td>
<td>ABC, 3TC, and a</td>
<td>ABC, 3TC, and a</td>
<td>Treatment-naïve</td>
<td>48</td>
<td>MEMS</td>
<td>Adherence</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td>third agent</td>
<td>third agent</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LaMarca [45]</td>
<td>2006</td>
<td>ABC/3TC (FDC) +</td>
<td>ABC + 3TC + TDF +</td>
<td>Experienced-failing</td>
<td>48</td>
<td>Pill count</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TDF + New</td>
<td>TDF + PI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NNRTI or PI</td>
<td>NNRTI or PI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portsmouth [51]</td>
<td>2006</td>
<td>D4T XR, 3TC, and</td>
<td>D4T or AZT, 3TC,</td>
<td>Experienced-controlled</td>
<td>24</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EFV</td>
<td>and EFV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruane [52]</td>
<td>2006</td>
<td>AZT, 3TC, ABC and</td>
<td>AZT, 3TC, ABC and</td>
<td>Experienced-controlled</td>
<td>24</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EFV</td>
<td>EFV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Molina [48]</td>
<td>2007</td>
<td>LPV/r, TDF and FT</td>
<td>LPV/r, TDF and FTC</td>
<td>Treatment-naïve</td>
<td>96</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Parienti [49]</td>
<td>2007</td>
<td>NVP and NRTIs</td>
<td>NVP and NRTIs</td>
<td>Experienced-controlled</td>
<td>16</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Boyle [42]</td>
<td>2008</td>
<td>D4T XR, 3TC, and</td>
<td>NRTIs and PI or NNRTI</td>
<td>Experienced-controlled</td>
<td>48</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EFV</td>
<td>NNRTI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maitland [46]</td>
<td>2008</td>
<td>ABC and 3TC</td>
<td>ABC and 3TC</td>
<td>Experienced-controlled</td>
<td>4</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Molina [47]</td>
<td>2008</td>
<td>ATV/r plus TDF-F</td>
<td>LPV/r plus TDF-F</td>
<td>Treatment-naïve</td>
<td>48</td>
<td>Pill count</td>
<td>Both</td>
<td>High</td>
</tr>
<tr>
<td>Campo [24]</td>
<td>2010</td>
<td>EFV plus NRTIs</td>
<td>EFV plus NRTIs</td>
<td>Experienced-controlled</td>
<td>48</td>
<td>Pill count</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Flexner [22]</td>
<td>2010</td>
<td>LPV/r and NRTIs</td>
<td>LPV/r and NRTIs</td>
<td>Treatment-naïve</td>
<td>48</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Gonzalez-Garcia[21]</td>
<td>2010</td>
<td>LPV/r, FTC, and</td>
<td>LPV/r, FTC, and TDF</td>
<td>Treatment-naïve</td>
<td>96</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Zajdenverg [19]</td>
<td>2010</td>
<td>LPV/r and NRTIs</td>
<td>LPV/r and NRTIs</td>
<td>Experienced-failing</td>
<td>48</td>
<td>MEMS</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Arasteh [18]</td>
<td>2011</td>
<td>NVP XR plus NRTIs</td>
<td>NVP IR plus NRTIs</td>
<td>Experienced-failing</td>
<td>24</td>
<td>Pill count</td>
<td>Both</td>
<td>Low</td>
</tr>
<tr>
<td>Cahn [17]</td>
<td>2011</td>
<td>DRV/r and NRTIs</td>
<td>DRV/r and NRTIs</td>
<td>Experienced-failing</td>
<td>48</td>
<td>Pill count</td>
<td>Both</td>
<td>Low</td>
</tr>
</tbody>
</table>

The generation of the allocation sequence was adequately reported in 8 studies (42%) and inadequately reported in 11 studies (58%). Potential risk of bias likely to be introduced by incomplete data was low in 16 studies (84%), unclear in 2 studies (11%), and high in 1 study [47] (imbalanced loss to follow-up). There was evidence of selective reporting in 3 studies (16%) that reported adherence alone. Most studies used intention to treat analysis (n = 18, 95%).

Abbreviations: 3TC, lamivudine; ABC, abacavir; ATV/r, atazanavir/ritonavir; AZT, zidovudine; d4T, stavudine; DRV/r, darunavir/ritonavir; EFV, efavirenz; FDC, fixed-dose combination; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; MEMS, Medication Event Monitoring System; NA, not applicable; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; TDF, tenofovir; XR, extended release.
correlation = −0.45; 95% CI, −.67 to −.16; *P* = .004) for both once-daily and twice-daily regimens. However, when the analysis was stratified by the regimens, the association between adherence and pill burden was significant in the twice-daily regimens (Spearman correlation = −0.67; 95% CI, −.86 to −.37; *P* = .001) but not in the once-daily regimens (Spearman correlation = −0.22; 95% CI, −.60 to .25; *P* = .35). There was also a statistically significant negative association (Figure 2B) between pill burden and virological suppression (Spearman correlation = −0.70; 95% CI, −.84 to −.49; *P* < .0001), which was significant in both the once-daily (Spearman correlation = −0.63; 95% CI, −.85 to −.23; *P* = .005) and twice-daily subgroups (Spearman correlation = −0.75; 95% CI, −.90 to −.44; *P* = .0003).

**Once-Daily Dosing**

When all populations were combined, mean adherence was slightly higher among participants following once-daily regimens than those following twice-daily regimens (WMD = 2.55%; 95% CI, 1.23–3.87; *P* = .0002; Figure 3). The trial sequential analysis demonstrated that for the regimens evaluated, the meta-analysis was conclusive (Supplementary Figure 1). In prespecified subgroup analyses, the greater average adherence with once-daily vs twice-daily dosing was more pronounced in treatment-naive patients (WMD = 3.94%; 95% CI, 1.42–6.47; *P* = .002; Figure 3) and treatment-experienced patients with virological failure switching to once-daily dosing (WMD = 5.28%; 95% CI, .60–9.96; *P* = .03; Figure 3) than in treatment-experienced patients who switched (for simplification/convenience) when their viral load was suppressed (WMD = 0.97%; 95% CI, .38–1.55; *P* = .53, Figure 3). These differences between subgroups were statistically significant (*P* = 0.02 for interaction). There was no significant difference in virological suppression among patients following once-daily vs twice-daily regimens (RR = 1.01; 95% CI, .98–1.03; *P* = .57; *I*² = 0%, Figure 4). Trial sequential analysis suggested that as of 2007 (after the ninth trial), sufficient evidence had accrued to demonstrate that the likelihood of finding a treatment effect was too low to justify further data collection. We therefore conclude that any possible intervention effect of once-daily regimens vs twice-daily regimens is lower than a 10% RR reduction in virological suppression (the prespecified threshold; Supplementary Figure 2). Furthermore, there was no significant difference between once- and twice-daily regimens in virological suppression in the treatment-naive or -experienced subgroups (Figure 4).

**Duration of Follow-up and Treatment Effects**

Adherence declined significantly over time (Spearman correlation = −0.41; 95% CI, −.64 to −.11; *P* = .009; Supplementary...
Figure 3. Forest plot of the effect of once-daily vs twice-daily antiretroviral regimens on the rate of adherence. Abbreviations: CI, confidence interval; IV, inverse variance; SD, standard deviation.

DISCUSSION

This meta-analysis of 19 RCTs which included 6312 patients found that higher pill burden was associated with both lower adherence and worse virological suppression in both twice-daily and once-daily subgroups. In addition, adherence was higher with once-daily ART regimens than with twice-daily regimens when adherence was measured objectively using pill counts and/or MEMS caps. However, this difference was minimal and did not translate into better treatment outcomes. Furthermore, the greater adherence with once-daily dosing was only statistically significant in treatment-naive individuals and in those who switched from twice- to once-daily dosing with virological failure. Adherence did not increase among treatment-experienced patients who switched from twice- to once-daily dosing while virologically suppressed; adherence was likely...
high in these patients prior to the switch. Both adherence and virological suppression decreased with longer follow-up, but the adherence decrease was less pronounced with once-daily dosing than with twice-daily dosing.

Interestingly, none of the included randomized trials directly evaluated the effect of an STR, which we consider an unanswered question for further research. However, in our study, there was a significant negative association between pill burden and virological suppression, suggesting that regimen simplification with STRs may be helpful in select situations. One small observational study conducted among marginally housed individuals and 2 large observational studies conducted found better adherence with STRs (compared with all other regimens, whether once daily or twice daily) [55, 56, 57], while 2 other observational studies found no difference between STRs and other once-daily regimens among patients starting ART [58] or among those who were switched from STR to multitablet regimens for reasons of cost [59].

There are several possible explanations for the apparent lack of impact of once- vs twice-daily dosing on virological outcomes. First, the impact of once-daily dosing on adherence was relatively small (2.5% absolute increase in adherence); this was possibly too small to result in a clinically meaningful difference in virological suppression. Second, a substantial number of the trials included in this meta-analysis were of relatively short duration. Moreover, volunteers for clinical trials

---

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Once-Daily Events</th>
<th>Total</th>
<th>Twice-Daily Events</th>
<th>Total</th>
<th>Weight</th>
<th>M-H, Random, 95% CI</th>
<th>M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.2.1 Treatment naive</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eron 2004 [43]</td>
<td>14</td>
<td>19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flexner 2010 [22]</td>
<td>98</td>
<td>161</td>
<td>105</td>
<td>159</td>
<td>1.9%</td>
<td>0.92</td>
<td>[0.78, 1.09]</td>
</tr>
<tr>
<td>Gallant 2006 [5]</td>
<td>194</td>
<td>244</td>
<td>171</td>
<td>243</td>
<td>4.9%</td>
<td>1.13</td>
<td>[1.02, 1.25]</td>
</tr>
<tr>
<td>Gonzalez-Garcia 2010 [21]</td>
<td>216</td>
<td>333</td>
<td>229</td>
<td>331</td>
<td>4.6%</td>
<td>0.94</td>
<td>[0.84, 1.04]</td>
</tr>
<tr>
<td>Molina 2007 [48]</td>
<td>66</td>
<td>115</td>
<td>40</td>
<td>75</td>
<td>0.8%</td>
<td>1.08</td>
<td>[0.83, 1.40]</td>
</tr>
<tr>
<td>Molina 2008 [47]</td>
<td>343</td>
<td>440</td>
<td>338</td>
<td>443</td>
<td>10.1%</td>
<td>1.02</td>
<td>[0.95, 1.10]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>1312</td>
<td>1270</td>
<td>22.7%</td>
<td></td>
<td></td>
<td>1.01</td>
<td>[0.94, 1.09]</td>
</tr>
</tbody>
</table>

Total events: 931 898
Heterogeneity: Tau² = 0.00; χ² = 8.02; df = 5 (P = .15); I² = 38%
Test for overall effect: Z = 0.35 (P = .73)

**1.2.2 Treatment experienced-controlled**

Arakelle 2011 [18] | 276 | 295 | 137 | 148 | 17.6% | 1.01 | [0.96, 1.07] |
| Benson 2004 [41] | 197 | 294 | 105 | 146 | 3.1% | 0.93 | [0.82, 1.06] |
| Boyle 2008 [42] | 164 | 205 | 72 | 95 | 3.0% | 1.06 | [0.92, 1.21] |
| Campo 2010 [24] | 101 | 125 | 100 | 128 | 3.4% | 1.02 | [0.90, 1.16] |
| Maitland 2008 [46] | 47 | 47 | 47 | 47 | 31.1% | 1.00 | [0.96, 1.04] |
| Patiendi 2007 [49] | 26 | 27 | 25 | 25 | 4.9% | 0.96 | [0.87, 1.07] |
| Portsmouth 2005 [51] | 20 | 22 | 18 | 21 | 1.1% | 1.06 | [0.85, 1.32] |
| Ruane 2006 [52] | 17 | 18 | 16 | 18 | 1.3% | 1.06 | [0.87, 1.30] |
| Sosa 2005 [53] | 105 | 130 | 106 | 130 | 3.8% | 0.99 | [0.88, 1.11] |
| **Subtotal (95% CI)** | 1163 | 756 | 69.3% | | | 1.00 | [0.97, 1.03] |

Total events: 953 626
Heterogeneity: Tau² = 0.00; χ² = 3.14; df = 8 (P = .93); I² = 0%
Test for overall effect: Z = 0.13 (P = .90)

**1.2.3 Treatment experienced-failing**

Cahn 2011 [17] | 212 | 294 | 210 | 296 | 5.1% | 1.02 | [0.92, 1.13] |
| Lamarche 2006 [45] | 47 | 94 | 41 | 87 | 0.6% | 1.06 | [0.79, 1.43] |
| Zalieuverg 2010 [19] | 166 | 300 | 155 | 299 | 2.4% | 1.07 | [0.92, 1.24] |
| **Subtotal (95% CI)** | 688 | 682 | 8.0% | | | 1.03 | [0.95, 1.12] |

Total events: 425 406
Heterogeneity: Tau² = 0.00; χ² = 0.33; df = 2 (P = .85); I² = 0%
Test for overall effect: Z = 0.82 (P = .41)

Total (95% CI): 3163 2708 100.0%

0.5 0.7 1 1.5 2
Favors twice-daily
Favors once-daily

Figure 4. Forest plot of the effect of once-daily vs twice-daily antiretroviral regimens on virologic suppression (plasma RNA HIV level <50 or <200 copies/mL). Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; M-H, Mantel-Haenszel.
are likely to be more adherent than their counterparts managed in routine clinical practice, and there may be more resources available to support adherence in clinical trial settings [60]. For these reasons, the difference in virological suppression that we found between once- and twice-daily ART regimens may be underestimated.

These results have several important practical implications. Currently, as all recommended regimens are highly potent, ART combinations should be selected based on factors such as tolerability, potential drug interactions, patient preference for dosing frequency, and pill burden, as well as structural factors (eg, cost, drug availability, access to care, insurance coverage) [61]. Efforts to improve and sustain adherence should not be limited to regimen simplification, but consideration should be given to proven evidence-based interventions to improve adherence such as social support [62], adherence support toolkits (eg, pillbox organizers) [63], use of cell phone and/or text messages, treatment supporters, and other targeted interventions when necessary [64–68].

In a mathematical simulation, Walensky and colleagues showed that the future use of a once-daily regimen that includes generic efavirenz plus generic lamivudine plus branded tenofovir in the United States could yield savings of almost $1 billion per year to HIV programs [69]. Our results suggest that these savings may be counterbalanced, in part, by worse virological outcomes if an increase in pill burden is required. However, no study, including ours, was specifically designed to directly investigate the impact of desimplification involving switching patients from once-daily STR to once-daily ART regimens containing multiple tablets. Further research is urgently needed to address this question.

Our study has several strengths. We performed a comprehensive search of several databases and sources to identify eligible RCTs that provide the highest quality of evidence. Three authors independently evaluated each study for inclusion and data extraction. Furthermore, we performed a trial sequential analysis; this is an efficient decision-making tool that is used to establish whether firm evidence of effect has been obtained [70]. Regarding limitations, most studies were of good quality with a low risk of bias. However, to the extent that their evidence was potentially biased, those biases are mirrored in our analyses. Notably, the likelihood of attrition bias, with a systematic difference between the 2 regimens in withdrawal rates, was very high in 1 study. While there was no evidence of heterogeneity in assessing virological suppression, the level of heterogeneity between studies in assessing adherence rates was high ($I^2 > 50\%$). Also, by focusing on once-daily vs twice-daily dosing, our analysis may have masked regimen-specific effects (eg, differences in toxicity) that have little to do with the frequency of dosing. Finally, the impact of regimen frequency and pill burden on adherence and virological outcomes in RCTs may not necessarily generalize to desimplification, in which patients may perceive that their regimen has been reduced in quality. Such a change could adversely affect adherence and/or treatment outcome, and, as noted above, specific studies to investigate this question are needed.

In this meta-analysis of 19 RCTs, we confirmed that once-daily ART regimens increased adherence when compared with twice-daily regimens, but the difference was modest and not associated with a difference in virological suppression. Importantly, we found that higher pill burden was associated with lower rates of virological suppression regardless of dosing frequency. The nonlinear correlation between pill burden and adherence or virological suppression suggests that, while ART desimplification from once-daily STRs to once-daily multitablet regimens may have adverse effects on virological outcomes, separating out STRs and/or fixed-dose combinations into their constituents is not likely to have a major detrimental impact on virological outcomes (provided that the overall pill burden does not increase dramatically). Nevertheless, further research is needed to directly investigate the impact of such a switch, in particular among patients who are virologically suppressed at baseline. In the meantime, our results suggest that pill burden should be a consideration in the selection of an antiretroviral regimen, independent of dosing frequency.

**Supplementary Data**

Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

**Notes**


**Acknowledgments.** We thank Dr Catherine Orrell, MBChB, University of Cape Town, and Dr Calvin Cohen, MD, Harvard Medical School, Boston, MA, for critical reading of this manuscript.

**Financial support.** There was no funding source for this study.

**Research grant support.** The US National Institutes for Allergy and Infectious Disease-National Institutes of Health (NIAID-NIH), AIDS Clinical Trial Group (ACTG), Stellenbosch University (SU)-Clinical Trial Unit (CTU) Award; 2UM1AI069521-08 (J. B. N.); the US NIH-Fogarty International Center (FIC)/Health Resources and Services Administration (HRSA)/US President Emergency Plan for AIDS Relief (PEPFAR) Grant Award, T84HA21652-01-00 for Medical Education Partnership Initiative (MEPI)
(J. B. N.); the European Developing Countries Clinical Trial Partnership (EDCTP) Senior Fellowship Award: TA-08-40200-021 (J. B. N.); the Wellcome Trust Southern Africa Consortium for Research Excellence (SACORE): Wt087537MA (J. B. N.); the National Institutes of Mental Health NIMH-NIH R34 MH083592-01A1 (E. J. M.). FAS Marie Curie International Post Doc: 2012-0064 (A. O. U.); the Penn Center for AIDS Research (CFAR), an NIH-funded program (P30 AI 045008) (R. G.). The Department of Veteran Affairs Health Services Research and Development Center Grant Award CIN 13-413 (T. P. G.). Agence Nationale de Recherche contre le SIDA (ANRS)/Institut National de la Santé et de la Recherche Médicale (INSERM) ATIP Avenir Post-Doc program: 2012–YY137 (J. J. P.); NIH Grant; NIAID-NIH Grant Award: UM1AI069412 (P. S.).

Role of the sponsor(s). The agencies had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The conclusions and opinions expressed in this article are those of the authors and do not necessarily reflect those of the NIH, the US Department of Health and Human Services, PEPFAR, HRSA, the Wellcome Trust, the US Department of Veterans Affairs, or the ANRS and INSERM.

Potential conflicts of interest. J. B. N. has received consulting fees for continuing medical education HIV lectures from Gilead Sciences, GlaxoSmithKline (GSK), and Boehringer-Ingelheim. J. J. P. has received research grant support or payment for conferences or participation at advisory boards from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb (BMS), Gilead Sciences, Janssen-Cilag, Merck-Sharp and Dohme (MSD), Tibotec, and ViViD Healthcare. J. G. has received research grant support from BMS, Gilead Sciences, MSD, Sangamo BioSciences, Vertex Pharmaceuticals, and ViViD Healthcare, as well as consulting fees for participation on advisory boards from Gilead Sciences, Janssen Therapeutics, and MSD. P. S. has received research grant support from BMS, Gilead Sciences, GSK, as well as consulting fees or honorarium from AbbVie, BMS, Gilead, GSK, Janssen, and MSD. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

3. Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD+ cell count is 0.200 to 0.350×10(9) cells/L. Ann Intern Med 2003; 139:810–6.


